Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Cash & Current Investments (2019 - 2025)

Historic Cash & Current Investments for Legend Biotech (LEGN) over the last 7 years, with Q3 2025 value amounting to $278.9 million.

  • Legend Biotech's Cash & Current Investments fell 3927.56% to $278.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $278.9 million, marking a year-over-year decrease of 3927.56%. This contributed to the annual value of $1.3 billion for FY2024, which is 4.64% down from last year.
  • As of Q3 2025, Legend Biotech's Cash & Current Investments stood at $278.9 million, which was down 3927.56% from $266.7 million recorded in Q2 2025.
  • Legend Biotech's Cash & Current Investments' 5-year high stood at $1.4 billion during Q2 2023, with a 5-year trough of $243.5 million in Q2 2024.
  • Moreover, its 5-year median value for Cash & Current Investments was $459.3 million (2024), whereas its average is $650.0 million.
  • In the last 5 years, Legend Biotech's Cash & Current Investments soared by 44662.56% in 2021 and then tumbled by 8284.29% in 2024.
  • Over the past 5 years, Legend Biotech's Cash & Current Investments (Quarter) stood at $690.4 million in 2021, then skyrocketed by 40.74% to $971.6 million in 2022, then surged by 31.57% to $1.3 billion in 2023, then tumbled by 77.56% to $286.8 million in 2024, then fell by 2.76% to $278.9 million in 2025.
  • Its Cash & Current Investments was $278.9 million in Q3 2025, compared to $266.7 million in Q2 2025 and $441.8 million in Q1 2025.